報價延遲最少15分鐘:2025/05/31 15:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.93/-0.93
|
|
企業價值
223.01M
|
| 資產負債 |
|
每股賬面淨值
1.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
683.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 15:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States. |